Skip to Main Content
Diseases of the Cardiovascular System | Hypertension, Phase II

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/​A011-16) (CADENCE)

What is the purpose of this trial?

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.

The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

  • Trial with
    Acceleron Pharma, Inc.
  • Ages
    18 years - 85 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Anna Hessler

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/23/2024
  • Study HIC
    #2000032349